Biogen BIIB reported adjusted fourth-quarter earnings of $8.34 per share on Thursday, which beat the analyst consensus estimate of $7.92 by 5.3%. This is a 19.31% increase over earnings of $6.99 per share from the same period last year.
The company reported quarterly sales of $3.67 billion, which beat the analyst consensus estimate of $3.52 billion by 4.26%. This is a 4.08% increase over sales of $3.526 billion the same period last year.
Biogen shares were trading down 0.096% at $282.25 in Thursday’s pre-market session. The stock has a 52-week high of $338.87 and a 52-week low of $215.78.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.